Increased infiltration of CCR4‐positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis

CCR4 Expression in Tumor-Infiltrating Regulatory T Cells in Patients with Squamous Cell Carcinoma of the Lung: A Prognostic Factor for Relapse and Survival

(2019) Nobuhiro Asai et al.   CANCER INVESTIGATION

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

(2018) et al.   JAMA Oncology

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

(2017) Maud Rijnders et al.   EUROPEAN UROLOGY

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

(2017) Chiara Berlato et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

(2017) Tomasz M. Beer et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy in genitourinary malignancies

(2017) Kathan Mehta et al.   Journal of Hematology & Oncology

FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer

(2017) Sabina Davidsson et al.   PROSTATE

Current status of immunotherapy

(2016) Susumu Suzuki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

(2016) Takuro Saito et al.   NATURE MEDICINE

Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study

(2015) Takashi Ishida et al.   BRITISH JOURNAL OF HAEMATOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

(2015) K. Kurose et al.   CLINICAL CANCER RESEARCH

Foxp3+cells are running the show in patients with surgically resected nonsmall cell lung cancer

(2015) Nathalie Chaput et al.   EUROPEAN RESPIRATORY JOURNAL

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

(2015) Koji Kurose et al.   Journal of Thoracic Oncology

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

(2015) Charles J Ryan et al.   LANCET ONCOLOGY

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The intratumoural subsite and relation of CD8+ and FOXP3+ T lymphocytes in colorectal cancer provide important prognostic clues

(2014) A Ling et al.   BRITISH JOURNAL OF CANCER

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

(2014) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Prostate cancer: ESMO Consensus Conference Guidelines 2012

(2013) A. Horwich et al.   ANNALS OF ONCOLOGY

Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches

(2013) Thomas Horn et al.   INTERNATIONAL JOURNAL OF CANCER

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

(2013) D. Sugiyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature

(2012) R. J. deLeeuw et al.   CLINICAL CANCER RESEARCH

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

(2012) Anna Flammiger et al.   EUROPEAN JOURNAL OF CANCER

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

(2009) M. Gobert et al.   CANCER RESEARCH

The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+regulatory T cells

(2009) Jacqueline P. Law et al.   CYTOMETRY PART A

Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor

(2009) Makoto Miyara et al.   IMMUNITY